HIV PrEP destined for PBS listing after historic PBAC recommendation

It's predicted to boost access and slash monthly costs for patients

HIV pre-exposure prophylaxis (PrEP) is set to be added to the PBS, boosting access and slashing the monthly cost to users from around $850 to $39.50.

The Pharmaceutical Benefits Advisory Committee (PBAC) announced on Friday its recommendation that Gilead's Truvada and two other emtricitabine/tenofovir treatments be listed.